Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Non invasive biomarkers for prostate cancer

AACR 2012

Published: 17 Apr 2012

Views: 6294

Rating:

Save

Dr David Ulmert - Memorial Sloan-Kettering Cancer Center, New York, USA; Dr Michael Evans - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Ulmert and Dr Evans talk with ecancertv at the AACR 2012 Annual Meeting about prostate specific antigens (PSA) and radiotracers for patients with prostate cancer, specifically castration resistant prostate cancer.

Dr Evans explains the how partnership between him and Dr Ulmert will hopefully result in developing non-invasive biomarkers, uncovering onco-genic signaling pathways, and using radiotracers to stage treatment response.

Related Videos

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

Choosing Wisely in endometrial & cervix cancers: Medical therapy

Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India

Choosing Wisely in endometrial & cervix cancers: Medical therapy ( Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

More from ecancer